Ann: Diagnostics update- Pipeline yields potential new biomarkers, page-2

Brilliant, this company is going from strength to strength , now a diversified product line of Biomarkers, with commercialised product that is producing revenue ,,, Territories for additional licenses in the "Discussion Stage"..
I note that the Giardia is well under way with a significant partner, Endometriosis identifier would save invasive surgery for discovery and eliminate a decade incubation period before identification..

The cost savings and patient welfare benefits are mind boggling ,, early identification is everything , progressed and established illness has far less remedies in the Tool Box ..

Our already signed Regions under license will have a suite of PIQ potentially life saving early identification tests to save patients lives and save Billions to Health systems..

Maybe this time we wont experience the ebb of the tide on the SP and stick with increasing value that reflects the company's Progress... NZT